Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvedBy |
gptkb:FDA
2023 advanced HR-positive, HER2-negative breast cancer |
| gptkbp:ATCCode |
L01EM07
|
| gptkbp:CASNumber |
1143532-39-1
|
| gptkbp:chemicalFormula |
C25H27ClN4O2S
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| https://www.w3.org/2000/01/rdf-schema#label |
capivasertib
|
| gptkbp:mechanismOfAction |
AKT inhibitor
|
| gptkbp:otherName |
gptkb:AZD5363
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue rash |
| gptkbp:target |
gptkb:AKT1
gptkb:AKT2 gptkb:AKT3 |
| gptkbp:usedFor |
gptkb:cancer
solid tumors |
| gptkbp:bfsParent |
gptkb:AZD5363
gptkb:V-akt_murine_thymoma_viral_oncogene_homolog_1 |
| gptkbp:bfsLayer |
7
|